BIOHIT is exhibiting at the BSI congress 2022

November 3, 2022

BIOHIT is excited to be exhibiting at this year’s British Society for Immunology (BSI) Congress in Liverpool. The UK’s premier immunology event, taking place from the 5th to 8th of December, welcomes over 1,500 attendees – including scientists, researchers and clinical specialists – to witness a fascinating fusion of innovative research from around the world.

The BSI Congress is an in-person and virtually accessible event with an exciting and comprehensive program, including an insightful presentation from Graham Johnson, Managing Director of BIOHIT, about GastroPanel®. This simple and non-invasive blood test assesses the structure and function of the stomach to accurately detect atrophic gastritis, a pre-neoplastic condition of the gastric mucosa associated with several autoimmune disorders, including autoimmune thyroiditis, pernicious and iron-deficiency anaemia. Visitors can also expect a wide range of other exciting seminars, covering topics such as neuroimmunology, tropical diseases, immunodeficiency, tissue immunology, immunotherapy and systems immunology.

The BIOHIT team will be showcasing its comprehensive range of therapeutic drug monitoring (TDM) assays at the conference too. These tests can determine a patient’s response to various treatments, providing critical information to guide clinicians’ decision-making in the development of individualised care plans for chronic inflammatory disease. And GastroPanel will also be on show, so visitors can learn about its potential to speed up investigative pathways for patients with digestive complaints. Representatives from BIOHIT will be at stand 31, and look forward to meeting as many guests as possible to demonstrate what the company can offer.

About BIOHIT HealthCare

BIOHIT HealthCare is a Finnish biotech company, headquartered in Helsinki, that specialises in the development, manufacture and distribution of kits and assays for the screening, diagnosis and monitoring of digestive diseases. Its core disease focus areas include stomach health and dyspepsia, reflux and acid dysregulation, Inflammatory Bowel Disease (IBD), functional gastrointestinal disorders (FGID), Irritable bowel syndrome (IBS), and gut microbiota dysbiosis. Innovating for Health

Recent Posts

Unboxing of Peptest

The inside edge on Peptest for the diagnosis of silent reflux

May 20, 2024
National Well-Being

The UK’s Health Landscape And The Endeavor For National Well-Being

May 10, 2024
Endoscopy in a hospital

Tackling the challenge of Helicobacter pylori in record time with the ULTRA-FAST UFT300 Quick Test

February 7, 2024

Exploring the value of biomarkers in gastric cancer screening

October 26, 2023